ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Files An 8-K Other Events
Item 8.01 Other Events.
On February 1, 2019, OncoSec Medical Incorporated (the “Company” or “OncoSec”) issued a press release reporting a clinical data update regarding KEYNOTE-695, as well as progress of its ongoing clinical development efforts and its outlook for 2019. A copy of the press release is being furnished as Exhibit 99.1 to this report.
On February 1, 2019, the Company posted an investor presentation to its website, www.oncosec.com. A copy of the investor presentation is being furnished as Exhibit 99.2 to this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are furnished herewith:
ONCOSEC MEDICAL Inc Exhibit
EX-99.1 2 ex99-1.htm ONCOSEC PROVIDES KEYNOTE-695 CLINICAL UPDATE AND OUTLINES 2019 MILESTONES — Tumor responses observed in 5 of first 21 patients,…
To view the full exhibit click here
About ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS)
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
